Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a worldwide safety surveillance study of pregnancy outcomes in women with hATTR-PN who may have been exposed or were not exposed to TEGSEDI prior to or during the pregnancy and of pediatric outcomes up to 1 year of age.
Enrollment
Sex
Volunteers
Inclusion criteria
TEGSEDI exposed patients (Cohort 1) meeting the following criteria will be eligible for study entry:
Unexposed patients (Cohort 2) meeting the following criteria will be eligible for study entry:
Exclusion criteria
None
20 participants in 2 patient groups
Loading...
Central trial contact
Amy Miller, RPh, Pharm D.; Ionis Pharmaceuticals
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal